Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...

AbbVie will not be pursued any further by the US government over allegations that it used 'sham' litigation to keep competition to its AndroGel testosterone replacement product off the market.

The company said it is keeping an eye on TNF-like ligand 1A (TL1A) therapies to be used in combination with Skyrizi which it hopes could become the new standard of care. AbbVie also spoke about ...